Key result
Supplementation with 4 g/day of ω-3 fatty acid ethyl esters significantly reduced postprandial triglyceride total AUC by 19% and VLDL-apoB-100 total AUC by 26% in patients with familial hypercholesterolemia.
Why the study?
Does omega-3 fatty acid ethyl ester supplementation reduce postprandial lipemia in patients with familial hypercholesterolemia on standard lipid-lowering therapy?
RCT (n=22)
Open-label
Randomized cross-over
No
Does omega-3 fatty acid ethyl ester supplementation reduce postprandial lipemia in patients with familial hypercholesterolemia on standard lipid-lowering therapy?
High-dose omega-3 fatty acid ethyl ester supplementation significantly improves postprandial lipemia in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy.
Answers are grounded in this paper and cite their sources.
Supports adjunctive omega-3 ethyl esters for postprandial lipemia control in FH; extends RCT evidence to dynamic responses on standard therapy.
CONTEXT: Impaired postprandial chylomicron metabolism induces hypertriglyceridemia and may increase the risk of atherosclerotic cardiovascular disease. Omega-3 fatty acid ethyl ester (ω-3 FAEE) supplementation decreases plasma triglycerides. However, its effect on postprandial chylomicron metabolism in familial hypercholesterolemia (FH) has not yet been investigated. OBJECTIVE: We aimed to examine the effect of ω-3 FAEE supplementation on postprandial responses in plasma triglycerides, very-low-density lipoprotein (VLDL) apolipoprotein B (apoB)-100, and apoB-48 in FH patients receiving standard cholesterol-lowering treatment. DESIGN, SETTING, AND PATIENTS: We carried out an 8-week open-label, randomized, crossover intervention trial to test the effect of oral supplementation with 4 g/d ω-3 FAEE (46% eicosapentaenoic acid and 38% docosahexaenoic acid) on postprandial triglyceride, VLDL-apoB-100, and apoB-48 responses in FH patients after ingestion of an oral fat load. OUTCOMES MEASURES: Plasma total and incremental triglyceride, VLDL-apoB-100, and apoB-48 0- to 10-hour area under the curve (AUC). RESULTS: ω-3 FAEE supplementation significantly (P < .05 in all) reduced concentrations of fasting plasma triglyceride (-20%), apoB (-8%), VLDL-apoB-100 (-26%), and apoB-48 (-36%); as well as systolic blood pressure (-6%) and diastolic blood pressure (-6%). Postprandial triglyceride and VLDL-apoB-100 total AUCs (-19% and -26%, respectively; P < .01) and incremental AUCs (-18% and -35%, respectively; P < .05), as well as postprandial apoB-48 total AUC (-30%; P < .02) were significantly reduced by ω-3 FAEE supplementation. CONCLUSION: Supplementation with ω-3 FAEEs improves postprandial lipemia in FH patients receiving standard care; this may have implications for further reducing atherosclerotic cardiovascular disease in this high-risk patient group.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2016) conducted an RCT in Familial Hypercholesterolemia (n=22). ω-3 Fatty Acid Ethyl Esters vs. No treatment was evaluated on Postprandial triglyceride, VLDL-apoB-100 and apoB-48 0-10 h area-under-the-curves (AUCs) (-19% (triglyceride total AUC), -26% (VLDL-apoB-100 total AUC), -30% (apoB-48 total AUC), p=<0.01). Supplementation with 4 g/day of ω-3 fatty acid ethyl esters significantly reduced postprandial triglyceride total AUC by 19% and VLDL-apoB-100 total AUC by 26% in patients with familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: